TY  - JOUR

T1  - Costs and effects in therapy for acute coronary syndromes: the case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Evaluation of 7E3 for the Prevention of Ischemic Complications.

JO  - Am Heart J

PY  - 1998/04/01

AU  - van Hout BA

AU  - Bowman L

AU  - Zelinger DJ

AU  - Simoons ML

ED  - 

DO  - DOI: 10.1016/s0002-8703(98)70302-3

VL  - 135

IS  - 4

SP  - S98

EP  - 106

Y2  - 2024/12/22

ER  -